全球開放式、一體化生物制藥能力和技術賦能平臺,專注于為全球生物制藥公司提供端到端研發服務的上市公司
藥(yao)(yao)(yao)明生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(股(gu)票代碼:2269.HK)作為(wei)一家香港上市公(gong)司,是全(quan)球(qiu)開放式、一體化生(sheng)(sheng)(sheng)物(wu)(wu)(wu)制藥(yao)(yao)(yao)能(neng)力和(he)技術賦能(neng)平臺。公(gong)司為(wei)全(quan)球(qiu)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)制藥(yao)(yao)(yao)公(gong)司和(he)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)技術公(gong)司提供端(duan)到端(duan)研(yan)發服務,幫助任(ren)何(he)人、任(ren)何(he)公(gong)司發現、開發及(ji)生(sheng)(sheng)(sheng)產(chan)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)藥(yao)(yao)(yao),實現從概念(nian)到商業(ye)化生(sheng)(sheng)(sheng)產(chan)的全(quan)過程,加速全(quan)球(qiu)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)藥(yao)(yao)(yao)研(yan)發進程,降低研(yan)發成本(ben),造福病患。截至2018年(nian)12月31日,在藥(yao)(yao)(yao)明生(sheng)(sheng)(sheng)物(wu)(wu)(wu)平臺上研(yan)發的綜(zong)合(he)(he)項(xiang)目達205個(ge),包括97個(ge)處(chu)于臨床前研(yan)究階段(duan),94個(ge)在臨床早期(qi)(I期(qi),II期(qi))階段(duan),13個(ge)在后期(qi)臨床(III期(qi))以及(ji)1個(ge)在商業(ye)化生(sheng)(sheng)(sheng)產(chan)階段(duan)。預(yu)計(ji)到2022年(nian),公(gong)司在中國(guo)、愛爾蘭、新加坡、美國(guo)規劃的生(sheng)(sheng)(sheng)物(wu)(wu)(wu)制藥(yao)(yao)(yao)生(sheng)(sheng)(sheng)產(chan)基地合(he)(he)計(ji)產(chan)能(neng)約22萬升,這將有力促(cu)使公(gong)司通(tong)過健全(quan)強大的全(quan)球(qiu)供應(ying)鏈(lian)網絡為(wei)客戶提供符合(he)(he)全(quan)球(qiu)質量標(biao)準的生(sheng)(sheng)(sheng)物(wu)(wu)(wu)藥(yao)(yao)(yao)。
藥(yao)(yao)(yao)明生(sheng)(sheng)(sheng)(sheng)(sheng)物是全(quan)球開放式、一(yi)體化(hua)生(sheng)(sheng)(sheng)(sheng)(sheng)物制藥(yao)(yao)(yao)能力和技術賦能平臺。公(gong)司為全(quan)球生(sheng)(sheng)(sheng)(sheng)(sheng)物制藥(yao)(yao)(yao)公(gong)司和生(sheng)(sheng)(sheng)(sheng)(sheng)物技術公(gong)司提供(gong)端到(dao)(dao)端研發(fa)服(fu)務,幫助任(ren)何(he)人、任(ren)何(he)公(gong)司發(fa)現(xian)、開發(fa)及生(sheng)(sheng)(sheng)(sheng)(sheng)產生(sheng)(sheng)(sheng)(sheng)(sheng)物藥(yao)(yao)(yao),實現(xian)從概(gai)念到(dao)(dao)商業化(hua)生(sheng)(sheng)(sheng)(sheng)(sheng)產的全(quan)過(guo)程(cheng)。公(gong)司通過(guo)高質量、一(yi)體化(hua)服(fu)務賦能全(quan)球客戶,提高研發(fa)效率,降(jiang)低研發(fa)成本,進一(yi)步加速(su)生(sheng)(sheng)(sheng)(sheng)(sheng)物藥(yao)(yao)(yao)研發(fa)進程(cheng)。